Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy

通过基因改造靶向人CD19和CD22受体的双特异性配体导向毒素，可提高其对抗系统性B细胞恶性肿瘤的疗效。